VINC

Vincerx Pharma, Inc. [VINC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VINC Stock Summary

In the News

VINC Financial details

Company Rating
-
Market Cap
20.99M
Income
-39.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.74
Forward P/E
-
PEG
0.23
P/S
-
P/B
1.88
P/C
-
P/FCF
-0.64
Quick Ratio
2.47
Current Ratio
2.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.85
EPS next Y
-
EPS next Q
-
EPS this Y
-30.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-50%
-
-
-
-
SMA20
-
SMA50
-91.38%
SMA100
-98.43%
Inst Own
-
Inst Trans
-
ROA
-152%
ROE
-131%
ROC
-3.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.61-9.372
52W High
-
52W Low
-
RSI
35.71
Rel Volume
0.06
Avg Volume
1.11M
Volume
67.4K
Perf Week
-8.33%
Perf Month
7.84%
Perf Quarter
-98.73%
Perf Half Y
-98.66%
-
-
-
-
Beta
0.808
-
-
Volatility
0%, 0%
Prev Close
-6.78%
Price
0.055
Change
10%

Something similar

Top by Market Cap
1YD.DE
GOOGL
VTI
FB2A.DE
BRH.DE
Same Sector
1951.HK
SLGL
6099.T
RYHTY
SPNE
Same Price Range
SRAX
EGLX.TO
8206.HK
0862.HK
AFMD
Similar Market Cap
HYEM.L
ACER
B8F.DE
MOTG
HEWG

Company Profile

Healthcare Biotechnology
  • Volume Average 1.11M
  • Market Capitalization 20.99M
  • Employee 42
  • CEO Dr. Ahmed M. Hamdy M.D.
  • Headquarters Palo Alto,CA,US
  • IPO Date 2020-05-27
  • Website https://vincerx.com

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.